Human Colorectal Cancer Organoids Group Standard 公告 2024-12-16 08:47:51 Written By Kym Kilbourne Title: Human Colorectal Cancer Organoids Group Standard Abstract The group standard "Human Colorectal Cancer Organoids" (T/CSCB0006-2022) is issued by the Chinese Society for Cell Biology, aiming to regulate the ethical requirements, technical requirements, and testing methods for human colorectal cancer organoids. This standard applies to the preparation and testing of patient-derived colorectal cancer organoids, providing a standardized operational guide for colorectal cancer research and treatment. Standard Content Scope This document specifies the definition, ethical requirements, technical requirements, and testing methods for human colorectal cancer organoids, ensuring that the preparation and testing processes are scientific and standardized. Normative References The standard references multiple documents, including diagnostic standards for Hepatitis C, AIDS, and HIV infection, to ensure the safety and effectiveness of organoid preparation and testing. Terms and Definitions Key terms such as organoids, tumor organoids, human colorectal cancer organoids, passage, cryopreservation, and revival are defined, providing a foundation for understanding and implementing the standard. Abbreviations Includes abbreviations such as DMSO, DNA, HBV, HCV, HIV, H&E, PBS, and STR, facilitating the rapid identification and use of professional terminology. Ethical Requirements Emphasizes the informed consent of organoid tissue donors, requiring the inclusion of research and treatment applications, potential commercialization of research results, and the protection of donor information. Technical Requirements 6.1 Morphology Specifies the morphological characteristics of human colorectal cancer organoids under an optical microscope, requiring clear edges, transparency, composed of cell clusters, and exhibiting specific morphologies. 6.2 In Vitro Culture and Growth Requires that colorectal cancer organoids derived from tumor tissue cells of patients with colorectal cancer can be maintained in vitro for 2 months after the initial culture and can be passaged for at least 3 generations. 6.3 Viability The viability of newly revived organoids should not be lower than 50%, and viable organoids can be passaged and cultured. 6.4 Microorganisms Requires that organoids test negative for fungi, bacteria, mycoplasmas, HBV, HCV, HIV, and exogenous viral factors. 6.5 STR STR testing and typing should be consistent with the donor's STR. 6.6 Pathological Morphology Requires that after H&E staining, the organoids are assessed by专业人员 to determine that the constituent cells exhibit atypical characteristics of tumor cells. 6.7 Genetic Characteristics Genetic mutation testing should be performed on organoids, with results consistent with the genetic mutations of the original tumor tissue. Testing Methods Detailed descriptions of the testing methods for morphology, quantity, viability, microorganisms, STR, pathological morphology, and genetic characteristics are provided, offering specific operational guidance for organoid testing. Appendix Includes specific steps and methods for organoid viability testing, STR identification, histopathological testing, and genetic mutation testing, providing detailed guidance for experimental operations. Conclusion The issuance of the "Human Colorectal Cancer Organoids" group standard provides a standardized framework for the research and application of human colorectal cancer organoids, helping to improve the quality and reliability of organoid preparation and testing, and promoting the advancement of colorectal cancer research and treatment. Kym Kilbourne
Human Colorectal Cancer Organoids Group Standard 公告 2024-12-16 08:47:51 Written By Kym Kilbourne Title: Human Colorectal Cancer Organoids Group Standard Abstract The group standard "Human Colorectal Cancer Organoids" (T/CSCB0006-2022) is issued by the Chinese Society for Cell Biology, aiming to regulate the ethical requirements, technical requirements, and testing methods for human colorectal cancer organoids. This standard applies to the preparation and testing of patient-derived colorectal cancer organoids, providing a standardized operational guide for colorectal cancer research and treatment. Standard Content Scope This document specifies the definition, ethical requirements, technical requirements, and testing methods for human colorectal cancer organoids, ensuring that the preparation and testing processes are scientific and standardized. Normative References The standard references multiple documents, including diagnostic standards for Hepatitis C, AIDS, and HIV infection, to ensure the safety and effectiveness of organoid preparation and testing. Terms and Definitions Key terms such as organoids, tumor organoids, human colorectal cancer organoids, passage, cryopreservation, and revival are defined, providing a foundation for understanding and implementing the standard. Abbreviations Includes abbreviations such as DMSO, DNA, HBV, HCV, HIV, H&E, PBS, and STR, facilitating the rapid identification and use of professional terminology. Ethical Requirements Emphasizes the informed consent of organoid tissue donors, requiring the inclusion of research and treatment applications, potential commercialization of research results, and the protection of donor information. Technical Requirements 6.1 Morphology Specifies the morphological characteristics of human colorectal cancer organoids under an optical microscope, requiring clear edges, transparency, composed of cell clusters, and exhibiting specific morphologies. 6.2 In Vitro Culture and Growth Requires that colorectal cancer organoids derived from tumor tissue cells of patients with colorectal cancer can be maintained in vitro for 2 months after the initial culture and can be passaged for at least 3 generations. 6.3 Viability The viability of newly revived organoids should not be lower than 50%, and viable organoids can be passaged and cultured. 6.4 Microorganisms Requires that organoids test negative for fungi, bacteria, mycoplasmas, HBV, HCV, HIV, and exogenous viral factors. 6.5 STR STR testing and typing should be consistent with the donor's STR. 6.6 Pathological Morphology Requires that after H&E staining, the organoids are assessed by专业人员 to determine that the constituent cells exhibit atypical characteristics of tumor cells. 6.7 Genetic Characteristics Genetic mutation testing should be performed on organoids, with results consistent with the genetic mutations of the original tumor tissue. Testing Methods Detailed descriptions of the testing methods for morphology, quantity, viability, microorganisms, STR, pathological morphology, and genetic characteristics are provided, offering specific operational guidance for organoid testing. Appendix Includes specific steps and methods for organoid viability testing, STR identification, histopathological testing, and genetic mutation testing, providing detailed guidance for experimental operations. Conclusion The issuance of the "Human Colorectal Cancer Organoids" group standard provides a standardized framework for the research and application of human colorectal cancer organoids, helping to improve the quality and reliability of organoid preparation and testing, and promoting the advancement of colorectal cancer research and treatment. Kym Kilbourne
